Trial Profile
A Phase III trial evaluating the tolerability of Grazax treatment in combination with antihistamine in subjects with seasonal grass pollen induced rhinoconjunctivitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2016
Price :
$35
*
At a glance
- Drugs Desloratadine (Primary) ; Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
- Focus Adverse reactions
- Sponsors ALK-Abello
- 03 Dec 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01740284).
- 29 Jul 2011 New trial record